Latest developments and future directions in dengue vaccines - Wikidata - wikimedia - TriplyDB

Latest developments and future directions in dengue vaccines

Latest developments and future directions in dengue vaccines

http://www.wikidata.org/entity/Q27023422

about

Recombinase Polymerase Amplification Assay for Rapid Diagnostics of Dengue Infection A community-based prospective cohort study of dengue viral infection in Malaysia: the study protocol Experiences with insecticide-treated curtains: a qualitative study in Iquitos, Peru Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment Is transfusion-transmitted dengue fever a potential public health threat?The Impact of Selection with Diflubenzuron, a Chitin Synthesis Inhibitor, on the Fitness of Two Brazilian Aedes aegypti Field Populations Dengue and Zika viruses: lessons learned from the similarities between these Aedes mosquito-vectored arboviruses Mapping the dengue scientific landscape worldwide: a bibliometric and network analysis Current perspectives on the spread of dengue in India.Field evaluation of picaridin repellents reveals differences in repellent sensitivity between Southeast Asian vectors of malaria and arboviruses.Describing the breakbone fever: IDODEN, an ontology for dengue fever.Factors Associated with Correct and Consistent Insecticide Treated Curtain Use in Iquitos, Peru.Honokiol, a Lignan Biphenol Derived from the Magnolia Tree, Inhibits Dengue Virus Type 2 Infection.Characterizing the Conformational Landscape of Flavivirus Fusion Peptides via Simulation and Experiment Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection.Recent progress in dengue vaccine development.Working towards dengue as a vaccine-preventable disease: challenges and opportunities.DEAD-Box Helicase DDX25 Is a Negative Regulator of Type I Interferon Pathway and Facilitates RNA Virus Infection.Computational predictions suggest that structural similarity in viral polymerases may lead to comparable allosteric binding sites.Using Wolbachia for Dengue Control: Insights from Modelling.Recent Developments in Recombinant Protein-Based Dengue Vaccines

P2860

Q24288657-C734F28B-211A-4F6F-AD36-DB175C7BD4DB Q26314376-E32A93F7-E7CA-474D-94D6-ADE88E4150BC Q26314576-F893DB38-2A73-4756-B823-D525087C29EB Q26314710-13191860-C4C0-4FDD-97DF-40BB47949160 Q27010609-C77D5428-DA40-4EE0-9C7E-C34852715030 Q28085648-4A1DEC00-A7BD-42F8-8C95-B1B6D4014E92 Q28548674-4FEE1189-FB25-4DD5-AA15-EDFDF3123646 Q28577861-1B6D87AE-E956-4864-81A4-34CB219B7E9C Q33583390-565D8D92-BB64-42B0-9397-240953B3C5F5 Q34700783-C250AD13-BF42-4130-A19B-44037CEE8E07 Q34732700-A91C46E5-7BAF-4003-B76B-6D87667ED51A Q35043859-DBB459ED-4178-44E8-A896-A666F09DF9E8 Q35953738-6BC04B85-C9CF-4D7C-B08A-3A71E10DBAFE Q36096412-398BE385-9785-4628-937A-51D1D911F66B Q36500499-FF685A91-C67E-4B75-AE81-069F3F724358 Q38248452-DD89D69D-CE74-4355-A17F-5FF408A1AC50 Q38303232-062069CA-BA74-4CE2-8849-416631F7C622 Q38657783-DF98D40D-4ACC-4FED-9595-20774C07AD92 Q39002042-65F54A33-BFA8-4CB4-B34D-A75418E16516 Q40102776-B9FF42F4-6923-47F5-8543-2014EDECA8A6 Q45880802-41E6113E-E908-4FF3-99F6-A2F51ABA8EAC Q56960671-6C09AE51-8BA2-4970-AB91-FCFC580B504A

P2860

Latest developments and future directions in dengue vaccines

http://www.wikidata.org/entity/Q27023422

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Latest developments and future directions in dengue vaccines

@ast

Latest developments and future directions in dengue vaccines

@en

Latest developments and future directions in dengue vaccines

@nl

type

label

Latest developments and future directions in dengue vaccines

@ast

Latest developments and future directions in dengue vaccines

@en

Latest developments and future directions in dengue vaccines

@nl

prefLabel

Latest developments and future directions in dengue vaccines

@ast

Latest developments and future directions in dengue vaccines

@en

Latest developments and future directions in dengue vaccines

@nl

P1433

Q27023422-C7F6E1DC-D2BB-4725-9387-A01CD0676B83

P1476

Q27023422-B049AFC4-C7A4-4837-BC7E-D3196EAAC7B1

P2093

Q27023422-063AEC6A-3943-4A4F-AA51-22DA52A590BF

Q27023422-8B642728-FFFF-4488-B7DF-0087D990CA8D

P2860

Q27023422-078C671A-A310-495A-9EAC-D21F303298DA

Q27023422-13F949F9-497D-4200-9454-3D3E0439C3F5

Q27023422-1BAA3AA1-A0B8-4694-A397-CBFBFA8CEA18

Q27023422-1C839EA4-0A39-454A-9ED3-F70FC5E22873

Q27023422-20AE4B4E-C164-4BAD-A3A5-14BBAC8B176F

Q27023422-20D013B5-E19C-4AF5-844F-845A5D349982

Q27023422-23E680E6-B682-4F4C-8A6B-7DE845A74BC9

Q27023422-2517D170-FE34-4112-808A-7F92C508BE69

Q27023422-2F615F42-A1A3-4962-963D-A456C754D9FD

Q27023422-3754971E-F33B-46C0-838A-330C416700DD

P304

Q27023422-BF25A1E1-E301-43D9-B507-7189AA297955

P31

Q27023422-ACE156E3-B251-491D-BB63-AE27E73293F0

P3181

Q27023422-FE0165DB-CCF6-4209-8FF3-CF72A092D3D2

P356

Q27023422-B009B84E-89E2-41C4-B689-633FF731FB07

P407

Q27023422-44986562-775D-4F11-9252-7B9BF3B86F25

P433

Q27023422-CA4D661C-DE57-4651-B3B9-8F5FC4CE93D4

P478

Q27023422-73980BFE-08FA-48C1-9C9F-1F32C15560F1

P577

Q27023422-D566FAF4-F22E-44F5-9A76-E2BD3059F7D9

P5875

Q27023422-AD8C9E46-8157-4C44-9CC1-BA9A8771AFE9

P698

Q27023422-2B8B5488-8DF8-46F0-9EAF-75F04B175FB9

P921

Q27023422-4F3181DC-D2E7-47A1-9BA2-EEF8F6B34229

Q27023422-637D628D-8DC2-4442-97E9-F1B7B72A1305

P932

Q27023422-86825A73-0784-410D-904F-32627A2812FC

P3181

P356

2051013613507862

P1433

Therapeutic advances in vaccines

P1476

Latest developments and future directions in dengue vaccines

@en

P2093

C. Thisyakorn

http://www.w3.org/2001/XMLSchema#string

U. Thisyakorn

http://www.w3.org/2001/XMLSchema#string

P2860

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast

Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.

Dengue infection: a growing global health threat.

Current progress in dengue vaccines

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

66543

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/2051013613507862

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261803006

http://www.w3.org/2001/XMLSchema#string

P698

24757522

http://www.w3.org/2001/XMLSchema#string

P921

vaccine development

P932

3991153

http://www.w3.org/2001/XMLSchema#string